US court rules for Novo Nordisk in Prandin patent listing dispute
This article was originally published in Scrip
Executive Summary
A recent US federal appeals court ruling means that Caraco Pharmaceutical, a subsidiary of Sun Pharmaceutical Industries, could face an uphill battle in its effort to introduce a generic version of Novo Nordisk's antidiabetic Prandin (repaglinide) and prove that it does not overlap and infringe the protected use.